Drug Trial Radar · NCT03061721
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
Last checked: Nov 20, 2026Latest source record: Oct 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Apr 6, 2017
Primary completion
Aug 22, 2019
Study completion Aug 22, 2019
Sponsor
- Lead sponsor
- Zydus Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 23, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study in up to 104 patients with a diagnosis of Non-alcoholic fatty Liver disease (NAFLD) and/or Non-alcoholic steatohepatitis (NASH). The study will be conducted over a period of up to 22 weeks and will include an optional Prescreening, Screening (Days -35 to -7) Phase, a 16-week Treatment Phase following randomization on Day 1. Patients will be randomly assigned in a ratio of 1:1:1:1 to receive Saroglitazar Magnesium 1mg or 2 mg or 4 mg or matching placebo once daily in the morning before breakfast for 16 Weeks. The primary endpoint of the study is percentage change from baseline in serum Alanine transaminase (ALT) levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group.
Conditions
- Non-Alcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis
Interventions
Saroglitazar magnesium 1 mgDrug
Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
Saroglitazar magnesium 2 mgDrug
Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
Saroglitazar magnesium 4 mgDrug
Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
PlacebosDrug
Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change From Baseline in Serum Alanine Aminotransferase (ALT) Levels at Week 16Time frame: Baseline and Week 16
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Precision Research
Chula Vista, California
Cedars-Sinai Medical Center
Los Angeles, California
Catalina Research Institute
Montclair, California
California liver research institute
Pasadena, California
Precision Research
San Diego, California
University of Florida
Gainesville, Florida
Schiff Center for Liver Diseases/University of Miami
Miami, Florida
Avail Clinical Research
Orange City, Florida
Indiana University
Indianapolis, Indiana
Mercy Medical Center
Baltimore, Maryland
University of Michigan
Ann Arbor, Michigan
Awasty Research Network, LLC
Marion, Ohio
Einstein Medical Center
Philadelphia, Pennsylvania
Gastro One
Germantown, Tennessee
AIG Research
Hermitage, Tennessee
Liver Consultants
Dallas, Texas
The Liver Institute
San Antonio, Texas
Swedish Medical Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.